Tagged as: Lannett

FDA Completes Safety Review of Lannett’s IND for Insulin Glargine Biosimilar

Lannett Company, Inc. (“Lannett”) announced Friday that the FDA has completed its safety review of Lannett’s Investigational New Drug application for Lannett’s insulin glargine biosimilar, a product Lannett is co-developing with its strategic alliance partners within the HEC group of companies, and has concluded that the company may proceed with…

Read More